Skip to content

Identification and Management of Comorbidities and Extra-intestinal Manifestations in Crohn's Disease: the NEMO Nurse-led Program

Identification and Management of Comorbidities and Extra-intestinal Manifestations in Crohn's Disease: the NEMO Nurse-led Program

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05254886
Acronym
NEMO-Nurse
Enrollment
198
Registered
2022-02-24
Start date
2022-12-12
Completion date
2027-01-01
Last updated
2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease

Brief summary

Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal (GI) tract. Although inflammation is predominantly expressed in the GI tract, extra-intestinal manifestations (EIMs) are so frequent that the concept of systemic disease is now widely accepted. Moreover, similar to other chronic diseases, patients with CD can be affected by other unrelated diseases which are called comorbidities. Although no specific guidelines on comorbidity and EIMs in CD are available, data from other immune-mediated diseases support the use of nurse-led programs to improve the cost-effectiveness for the management of cardiovascular risk factors, increase rates of pneumococcal vaccination in high-risk patients, provide preventive measures against osteoporosis and increased fracture risk in older women. The investigators believe that such an initiative can be conducted for CD patients by developing a CD-specific nurse-led program. Moreover, it has been shown that CD patients highly appreciate the communicator role and skilled companionship performed by nurses to fulfill their needs for attention to the complete picture. Therefore, the investigators hypothesize that a nurse-led program would increase the number of measures taken to treat or identify EIMs and/or comorbidities in CD patients and thus revolutionize their management.

Interventions

OTHERNEMO nurse-led program

The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will: * Report the presence of pre-existing comorbidities/EIMs * Detect the presence of risk factors * Implement recommendations for the detection and/or management of comorbidities/EIMs.

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

* Established diagnosis of CD with a minimum disease duration of 3 months * CD considered by the treating gastroenterologist to have been stable for at least 3 months * No surgery planned within 6 months after the inclusion visit

Exclusion criteria

* Subject unable to attend all the study visits or comply with study procedures. * Subject unwilling or not able to understand or sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Number of measures taken by a physician in order to prevent or treat comorbidities and EIMs associated with CD6 months

Secondary

MeasureTime frameDescription
Number of measures taken by a physician for each comorbidity and EIM associated with CD in order to prevent or treat them6 months
Percentage of patients who comply with recommendations issued by the nurse following completion of the NEMO nurse-led program6 months
Level of patient satisfaction with the NEMO nurse-led program6 monthsAssessment with a Satisfaction Questionnaire. Answer options are presented on a 4-item Likert scale and ranges from 1 ('Not at all satisfied') to 4 ('Very satisfied'). Total score is summed up and ranges from 14 to 56, higher score indicating higher levels of satisfaction.
Frequency of comorbidities and EIMs, confirmed by a medical specialist, associated with CD6 months

Countries

France, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026